Last updated on: 22/09/2022
Name of organisation
1) Department/Research groupDrugs and Pregnancy
2) Organisation/affiliationFinnish Institute for Health and Welfare, THL
Short Name in the inventoryDrugs and Pregnancy
Administrative Contact
Title Dr
Last name Leinonen
First name Maarit
Address line 1P.O. BOX 30
Address line 2
Address line 3
CityHelsinki
Postcode00271
CountryFinland
Phone number (incl. country code)358295247640
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Dr
Last name Leinonen
First name Maarit
Address line 1P.O. BOX 30
Address line 2
Address line 3
CityHelsinki
Postcode00271
CountryFinland
Phone number (incl. country code)358295247640
Alternative phone number
Fax number (incl. country code)
2. Description
The 'Drugs and pregnancy ' project' is a co-project of the Finnish Medicines Agency (Fimea), the National Institute for Health and Welfare (THL), and the Social Insurance Institution of Finland (Kela). The project started in 2008 and was preceded by a previous pilot study (2003-2007).
Data in 'Drugs and pregnancy ' are based on the national health registers of Finland, including information on all pregnancies in Finland 1996-2020 ending in birth (n=1 407 846) or abortion (n=252 833). Information on perinatal health and malformations, maternal reimbursed drug purchases and chronic diseases prior to and during pregnancy is included in the data. The data are annually cumulating.
The aim of the project is to evaluate the pattern of drug use during pregnancy and to estimate the effect of drug use on pregnancy outcomes, including perinatal health and major congenital anomalies.
3. Category
Government based
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
No
Statistician
Yes
No
Clinician
Yes
No
Geneticist/Pharmacogeneticist
Yes
No
IT specialist
Yes
No
Legal expertise
Yes
No
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Congenital Malformations
Malignant disease
Neonates
Paediatrics
Pregnancy
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Less than 5
Number of patients/respondents involved in the study(ies)
Between 150 and 1499
8. Access to data collection resources
Capacity to conduct face-to-face interviews
No
Electronic data capture systems
Yes
System used:
Oracle
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Medical Birth Register13
Register of Congenital Malformations4
Register of Induced Abortions1
Hospital Discharge6
Cancer Registry6
11. Registries established by centre
Other national research database on drug exposure during pregnancy, perinatal health and major malformations
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
EUROCAT
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Bjørk M, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, Gilhus NE, Gissler M, Halfdanarson O, Igland J, Sun Y, Tomson T, Alvestad S, Christensen J. Association of Prenatal Exposure to Antiseizure Medication with Risk of Autism and Intellectual Disability JAMA Neurology 2022; 79(7): 672-681.https://jamanetwork.com/journals/jamaneurology/fullarticle/2793003
Halfdanarson O, Cohen JM, Karlstad Ø, Cesta CE, Bjørk MH, Håberg SE, Einarsdóttir K, Furu K, Gissler M, Hjellvik V, Kieler H, Leinonen MK, Mette Nørgaard M, Essen BÖ, Ulrichsen SP, Reutfors J, Zoega H. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: A Nordic cohort study and sibling analysis. Evid Based Ment Health 2022; 25(2): 54-62.https://ebmh.bmj.com/content/25/2/54
Hjorth S, Hemmingsen CH, Benevent J, Broe A, Pottegaard A, Mørch L, Leinonen MK, Kjaer SK, Hargreave M, Nordeng H. Maternal Medication Use and Childhood Cancer in Offspring – Systematic Review and Considerations for Researchers. Am J Epidemiol 2021; 190(11): 2487-2499.https://academic.oup.com/aje/article/190/11/2487/6279410?login=true
Cesta CE, Cohen JM, Pazzagli L, Bateman BT, Bröms G, Einarsdóttir K, Furu K, Havard A, Heino A, Hernandez-Diaz S, Huybrechts KF, Karlstad Ø, Kieler H, Li J, Leinonen MK, Løvdal Gulseth H, Tran D, Yu Y, Zoega H, Odsbu I. Antidiabetic Medication Use during Pregnancy: An International Utilization Study. BMJ Open Diabetes Res Care 2019; 7 (1): e000759.https://pubmed.ncbi.nlm.nih.gov/31798900/
